Author: Patricia Rios; Amruta Radhakrishnan; Sonia M. Thomas; Nazia Darvesh; Sharon E. Straus; Andrea C. Tricco
Title: Guidelines for preventing respiratory illness in older adults aged 60 years and above living in long-term care: A rapid review of clinical practice guidelines Document date: 2020_3_26
ID: kwncu3ji_419
Snippet: The widespread use of antivirals in institutions that house residents at high risk of severe disease and death from influenza is supported by observational cohort studies and one randomised controlled trial. During an outbreak, other facility residents will have been, or may become, exposed to infectious residents. The provision of antivirals works as early treatment for those incubating disease and reduces shedding in those infected. Data are av.....
Document: The widespread use of antivirals in institutions that house residents at high risk of severe disease and death from influenza is supported by observational cohort studies and one randomised controlled trial. During an outbreak, other facility residents will have been, or may become, exposed to infectious residents. The provision of antivirals works as early treatment for those incubating disease and reduces shedding in those infected. Data are available to support the premise that this treatment/shedding reduction process prevents continued spread in the facility. (Appendix 16) Antiviral prophylaxis should only be used in addition to other outbreak control measures. The decision to administer antivirals as prophylaxis should be made by the OMT in collaboration with local public health authorities and residents' GPs, depending on local arrangements. If recommended, to optimise the chances of reducing transmission and bring the outbreak under control, antiviral prophylaxis should be given to ALL asymptomatic residents (regardless of vaccination status) and ALL unvaccinated staff.
Search related documents:
Co phrase search for related documents- antiviral prophylaxis and cohort study: 1, 2, 3
- antiviral prophylaxis and early treatment: 1, 2, 3, 4, 5, 6
- antiviral prophylaxis and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- asymptomatic resident and cohort study: 1
- asymptomatic resident and facility resident: 1, 2
- asymptomatic resident and high risk: 1
- cohort study and continue spread: 1
- cohort study and control trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- cohort study and death severe disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- cohort study and early treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cohort study and facility resident: 1, 2, 3, 4
- cohort study and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cohort study and infect shed: 1
- continue spread and high risk: 1, 2, 3, 4
- control trial and death severe disease: 1
- control trial and early treatment: 1, 2, 3, 4, 5, 6, 7
- control trial and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- death severe disease and facility resident: 1
- death severe disease and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date